Core Insights - Crystal Technology (2228.HK) announced a pipeline collaboration with DoveTree, with a total order value of approximately HKD 47 billion (USD 5.99 billion) [1] - The company has received an initial payment of approximately HKD 400 million (USD 51 million) as part of the agreement [1] - The collaboration involves multiple preclinical stage large and small molecule innovative drug assets, with DoveTree holding exclusive global development and commercialization rights [1] Financial Details - In addition to the initial payment, Crystal Technology is entitled to receive further payments of approximately HKD 385 million (USD 49 million) [1] - There is potential for milestone payments and sales shares amounting to approximately HKD 462 billion (USD 58.9 billion) [1] - This collaboration sets a new record in the AI and robotics drug development sector in terms of order size [1]
晶泰科技：与DoveTree完成总订单规模约470亿港元的管线合作签约
Xin Lang Cai Jing·2025-08-06 01:07